| | |
|---|---|
| **Name** | Ja Min Byun |
| **Current Position & Affiliation** | Associate professor / Seoul National University Hospital |
| **Country** | Korea |
| **Major Field** | Lymphoid Malignancies |

| **Educational Background** |
|---|
| 2004 – 2010 Kyung Hee University College of Medicine, Seoul, Korea<br>2013-2015 Master's degree, Kyung Hee University, Seoul, Korea<br>2015-2019 Doctor of Philosophy, Seoul National University, Seoul, Korea |

| **Professional Experience** | |
|---|---|
| 2010.3 – 2011.2 | Internship in Kyung Hee University Hospital, Seoul, Korea |
| 2011.3 – 2015.2 | Residency in the Department of Internal Medicine, Kyung Hee University Hospital , Seoul, Korea |
| 2015.3 – 2017.2 | Clinical fellowship in the Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea |
| 2016.7 – 2016.8 | Visiting scientist at Ontario Institute for Cancer Research (OICR), Toronto, Ontario, Canada |
| 2017.3 – 2019.5 | Clinical assistant professor in the Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea |
| 2019.06 – 2023.08 | Assistant professor in the Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea |
| Sept. 2023 – Present | Associate professor in the Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea |

| **Other Experience and Professional Memberships** | |
|---|---|
| 2015 – Present | Member, Korean Society of Hematology (KSH) |
| 2018 – Present | Member, American Society of Hematology (ASH) |
| 2021 – Present | Member, iwCLL Global Partnership Subcommittee |
| 2022 – Present | Member, European Hematology Association (EHA) |
| 2024 - Present | Member, Asia Myeloma Network (AMN) |
| 2022 | Reviewer and session moderator, 64th American Society of Hematology (ASH) Annual Meeting: Health services and quality – Lymphoid malignancies |

| | |
|---|---|
| 2022- Present | Member, Korean Society of Blood and Marrow Transplantation Scientific Committee |
| 2024 | Reviewer, EHA 2024 Hybrid Congress: Myeloma and other monoclonal gammopathies – clinical |
| 2024 | Reviewer, 66th ASH Annual Meeting: Chronic Lymphocytic Leukemia - Clinical and Epidemiological |
| 2024-Present | Member, KSH International Affairs Committee |
| 2025 | Reviewer, XXI iwCLL 2025 |

## Main Scientific Publications

- Byun JM#, Kim S-A, Koh Y, Shin D-Y, Kown JH et al. Limited benefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea. Curr Probl Cancer. 2022 Feb;46(1):100786
- Byun JM#, Min C-K, Kim K, Bang S-M, Lee J-J et al. Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease Running title: DARA-DCEP for R/R MM with EMD. J Hematol Oncol. 2022 Oct 23;15(1):150
- Byun JM#, Kim HY, Nam S-H, Shin H-J, Song S, et al. A multicenter, open-labe study for efficacy and safety evaluation of anagrelide in patients with treatment-naïve, high-risk essential thrombocythemia as a primary treatment. Front Oncol. 2022 Nov 23:12:989984
- Shin J, Lee JY, Lee G-W, Kim WS, Park Y, Do YR, Kim DS, Kim KH, Choi YS, Byun JM, Hong J, Kim I, Yoon S-S, Koh Y. Phase II study of bortezomib, cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma. Br J Haematol. 2023 Sep;202(6):e54-e57
- Byun JM#, Shin J, Kim S-A, Park H, Lee J, et al. A Phase II Study to Evaluate the Efficacy of Bortezomib in Combination with Thalidomide in Treatment-Naïve Waldenstrom Macroglobulinemia Patients. Cancer Res Treat. 2024 Apr;56(2):675-680
- Kim DH, Hong J, Shin D-Y, Kim I, Yoon S-S, Bang SM, Lee J-O, Lee JY, Kim S-A, Byun JM*, Koh Y*. Phase II trial of posaconazole prophylaxis during anti-thymocyte globulin treatment for aplastic anemia and hypoplastic myelodysplastic syndrome. Br J Haematol. 2024 Jul;205(1):356-359
- Park C, Lee HS, Kang K-W, Lee W-S, Do YR, Kwak J-Y, Shin H-J, Kim S-Y, Yi JH, Lim S-N, Lee J-O, Yang D-H, Jang H, Choi Y, Lim J, Sun CH, Byun JM, Yoon S-S, Koh Y. Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial. Nat Commun. 2024 Mar 30;15(1):2776
- Bumma N, Richter J, Jagannath S, Lee HC, Hoffman JE, Suvannasankha A, Zonder JA, Shah MR, Lentzch S, Baz R, Silberman R, Min C-K, Vekemans M-C, Munder M, Byun JM, Martinez-Lopez J, et al. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2024 Aug 1;42(22):2702-2712.
- Kim DH, Park T, Hong J, Shin DY, Kim I, Yoon SS, Byun JM* Koh Y. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide conditioning in patients with central nervous system lymphoma: a phase II study. Ann Hematol. 2025 Jul;104(7):3843.
- Kang M#, Kharbash R#, Byun JM#, Jeon J, Ali AA, et al. Double-stranded RNA induction as a potential dynamic biomarker for DNA-demethylating agents. Mol Ther Nucleic Acids. 2022 Jul 21:29:370-383
- Lee S, Sun C-S, Jang H, Kim D, Yoon S-S, Koh Y, Na SC, Cho SI, Kim MJ, Seong M-W, Byun JM*, Yun H*. ITDetect: A method to detect internal tandem duplication of FMS-like tyrosine kinase (FLT3) from next-generation sequencing data with high sensitivity and clinical application. BMC Bioinformatics. 2023 Feb 23;24(1):62

- Liu J, Min S, Kim D, Park J, Park E, Koh Y, Shin D-Y, Kim TK, Byun JM, Yoon S-S, Hong J. Epigenetic priming improves salvage chemotherapy in diffuse large B-cell lymphoma via endogenous retrovirus-induced cGAS-STING activation. Clin Epigenetics. 2023 May 3;15(1):75
- Liu J, Min S, Kim D, Park J, Park E, Pei S, Koh Y, Shin D-Y, Byun JM, Ko M, Yoon S-S, Hong J. Pharmacological GLUT3 salvage augments the efficacy of vitamin C-induced TET2 restoration in acute myeloid leukemia. Leukemia. 2023 Aug;37(8):1638-1648
- Kim DW[#], Byun JM[#], Lee J-O, Kim JK, Koh Y. Chemotherapy delivery time affects treatment outcomes of female patients with diffuse large B-cell lymphoma. JCI Insight. 2023 Jan 24;8(2):e164767
- Park S-S[#], Lee JC[#], Byun JM[#], Choi G, Kim KH, et al. Machine learning-based sequential analysis to assist selection between bortezomib-melphalan-prednisolone and lenalidomide-dexamethasone for newly diagnosed multiple myeloma. NPJ Precis Oncol. 2023 May 20;7(1):46
- Chun C[#], Byun JM[#], Cha M[#], Lee H, Choi B, et al. Profiling protein-protein interactions to predict the efficacy of B-cell-lymphoma-2-homology-3 mimetics for acute myeloid leukaemia. Nat Biomed Eng. 2024 Nov;8(11):1379-1395